| Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma. | |
| | |
MedLine Citation:
|
PMID: 19820959 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The aim of this study was to evaluate the efficacy and the toxicity of paclitaxel and cisplatin in patients in concurrent radiotherapy for locally advanced nasopharyngeal carcinoma, and to see whether such a regime would be better tolerated than high dose cisplatin plus fluoracil in Chinese patients. Thirty-one patients with locally advanced nasopharyngeal carcinoma were enrolled. Patients were scheduled to receive two courses of concomitant chemotherapy, starting on day 1 and then day 28 during radiotherapy (70-76 Gy in 35-38 fractions in 7-7.5 weeks). Chemotherapy was given by intravenous infusion, paclitaxel 120 mg/m(2) in 3 h, cisplatin 75 mg/m(2) (25 mg/m(2) days 1-3). Adjuvant therapy was paclitaxel 135 mg/m(2) in 3 h, cisplatin 75 mg/m(2) (25 mg/m(2) days 1-3) on weeks 3, 6, 9 after radiotherapy. All patients completed radiotherapy, but for concomitant chemoradiotherapy, 20 of the 31 patients completed the 2 cycles of chemotherapy, while the other 11 could only receive 1 cycle due to various reasons. The median follow-up was 40 months, 2 patients developed locoregional recurrences, one of whom in the cervical lymph nodes, the other in the nasopharynx. The 3-year overall survival rate was 83.9% and the distant metastasis rate at 3 years was 13.6%. Grade 3-4 toxicities were neutropenia 12.9%, anaemia 6.45%, thrombocytopenia 3.22%, severe arrhythmia 3.2%, and hypersensitivity reaction 3.2%. In conclusion, paclitaxel with cisplatin as concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma is feasible, safe, and might improve regional control and survival rates in Chinese patients. |
| | |
Authors:
|
Xia-Yun He; Chao-Su Hu; Hong-Mei Ying; Yong-Ru Wu; Guo-Pei Zhu; Tai-Fu Liu |
Related Documents
:
|
9045329 - Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide... 9428489 - Vinorelbine and cisplatin (civic regimen) for the treatment of metastatic breast carcin... 9007139 - Phase i/ii study of paclitaxel and radiotherapy in non-small cell lung cancer. 14676119 - Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxoru... 9331119 - Paclitaxel (3-hour infusion) followed by carboplatin (24 hours after paclitaxel): a pha... 10080589 - Multicenter phase ii study of capecitabine in paclitaxel-refractory metastatic breast c... 19152449 - Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer... 16582119 - Prediction of persistence or recurrence after conization for cervical intraepithelial n... 3569329 - Primary tumor receptorial status and axillary metastases: their prognostic significance. |
Publication Detail:
|
Type: Journal Article Date: 2009-10-10 |
Journal Detail:
|
Title: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery Volume: 267 ISSN: 1434-4726 ISO Abbreviation: Eur Arch Otorhinolaryngol Publication Date: 2010 May |
Date Detail:
|
Created Date: 2010-03-24 Completed Date: 2010-08-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9002937 Medline TA: Eur Arch Otorhinolaryngol Country: Germany |
Other Details:
|
Languages: eng Pagination: 773-8 Citation Subset: IM |
Affiliation:
|
Department of Radiation Oncology, Cancer Hospital, Fudan University, 399 Ling Ling Road, 200032, Shanghai, People's Republic of China. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Antineoplastic Agents / therapeutic use* Antineoplastic Agents, Phytogenic / therapeutic use* Carcinoma, Squamous Cell / drug therapy*, pathology, radiotherapy* Cisplatin / therapeutic use* Drug Therapy, Combination Female Humans Magnetic Resonance Imaging Male Middle Aged Nasopharyngeal Neoplasms / drug therapy*, pathology, radiotherapy* Paclitaxel / therapeutic use* Radiotherapy Dosage Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Antineoplastic Agents, Phytogenic; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Craniocerebral injury resulting from pencil penetration.
Next Document: Fat oxidation rate during and after a low- or high-intensity exercise in severely obese Caucasian ad...